New directions in the treatment of systemic lupus erythematosus

References

• Vasoo S, Hughes GR. Theory, targets and therapy in systemic lupus erythematosus. Lupus 2005;14:181-8
   PubMed Web of Science ®Google Scholar
• Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006;15:308-18
   PubMed Web of Science ®Google Scholar
• Manzi S. Epidemiology of systemic lupus erythematosus. Am J Manag Care 2001;7(16 Suppl.):S474-9
   PubMed Web of Science ®Google Scholar
• Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205
   PubMed Web of Science ®Google Scholar
• Ramsey-Goldman R, Manzi S. Systemic lupus erythematosus. In: Women and Health Goldmanc MB, Hatch MC, eds. San Diego, CA, USA: Academic Press, 2000:704-23
   Google Scholar
• Jonsson H, Nived O, Sturfelt G, Silman A. Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol 1990;29:185-8
   PubMedGoogle Scholar
• Somers EC, Thomas SL, Smeeth L, et al. Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999. Arthritis Rheum 2007;57:612-18
   PubMed Web of Science ®Google Scholar
• Swaak AJ, van den Brink HG, Smeenk RJ, et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford) 1999;38:953-8
   PubMed Web of Science ®Google Scholar
• Haubitz M. Exploring new territory: the move towards individualised treatment. Lupus 2007;16:227-31
   PubMed Web of Science ®Google Scholar
• Anolik JH. B cell biology and dysfunction in SLE. Bull NYU Hosp Jt Dis 2007;65:182-6
   PubMedGoogle Scholar
• d’Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369:587-96
   PubMed Web of Science ®Google Scholar
• Pascual V, Banchereau J, Palucka AK. The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 2003;15:548-56
   PubMed Web of Science ®Google Scholar
• Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992;35:311-18
   PubMed Web of Science ®Google Scholar
• Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004;50:849-57
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Roseman JM, McGwin Jr G, et al. Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. LUpus in MInority populations: NAture vs Nurture. Lupus 2000;9:101-9
   PubMed Web of Science ®Google Scholar
• Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Rheum 2007;57:1348-57
   PubMed Web of Science ®Google Scholar
• Fairhurst AM, Wandstrat AE, Wakeland EK. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 2006;92:1-69
   PubMed Web of Science ®Google Scholar
• Petri M. Treatment of systemic lupus erythematosus: an update. Am Fam Physician 1998;57:2753-60
   PubMed Web of Science ®Google Scholar
• Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford) 2007;46:895-8
   PubMed Web of Science ®Google Scholar
• Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004;50:1709-20
   PubMed Web of Science ®Google Scholar
• Strand V. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions. Lupus 2004;13:406-11
   PubMed Web of Science ®Google Scholar
• Isenberg DA. BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM. thank you MAM. Lupus 2007;16:849-51
   PubMed Web of Science ®Google Scholar
• Mok CC. Cyclophosphamide for severe lupus nephritis: where are we now?. Arthritis Rheum 2004;50:3748-50
   PubMed Web of Science ®Google Scholar
• Harris Jr ED, Budd RC, Firestein GS, et al. Aggressive therapy. In:Kelly's Textbook of Rheumatology, 7th edn. Philadelphia, PA, USA: Elsevier Saunders, 2004
   Google Scholar
• Gordon C. Long-term complications of systemic lupus erythematosus. Rheumatology (Oxford) 2002;41:1095-100
   PubMed Web of Science ®Google Scholar
• Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006;85:147-56
   PubMed Web of Science ®Google Scholar
• Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999;92:211-18
   PubMed Web of Science ®Google Scholar
• Mok CC, Lee KW, Ho CT, et al. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 2000;39:399-406
   PubMed Web of Science ®Google Scholar
• Nossent J, Cikes N, Kiss E, et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus 2007;16:309-17
   PubMed Web of Science ®Google Scholar
• Gillis JZ, Yazdany J, Trupin L, et al. Medicaid and access to care among persons with systemic lupus erythematosus. Arthritis Rheum 2007;57:601-7
   PubMed Web of Science ®Google Scholar
• Harris Jr ED, Budd RC, Firestein GS, et al. Conservative management. In:Kelly's Textbook of Rheumatology, 7th edn. Philadelphia, PA, USA: Elsevier Saunders, 2004
   Google Scholar
• DiCesare PE, Zuckerman JD. Articular manifestations of systemic lupus erythematosus. In: Lahita RG, ed. Systemic Lupus Erythematosus, 3rd edn. San Diego, CA, USA: Academic Press, 1999:793-812
   Google Scholar
• MacGowan JR, Ellis S, Griffiths M, et al. Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology (Oxford) 2002;41:981-7
   PubMed Web of Science ®Google Scholar
• Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. Lupus 2007;16:212-16
   PubMed Web of Science ®Google Scholar
• Kanno A, Hotta O, Yusa N, et al. Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy. Ren Fail 2007;29:41-7
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Appel GB, Dooley MA, et al. Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): efficacy by racial group. American College of Rheumatology Annual Congress, Boston, MA, November 6-11, 2007 [Abstract No. L13].
   Google Scholar
• McMahon M, Grossman J, Fitzgerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9
   PubMed Web of Science ®Google Scholar
• Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15
   PubMed Web of Science ®Google Scholar
• Mok CC, Tang SS, To CH, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52:2774-82
   PubMed Web of Science ®Google Scholar
• Merrill JT. Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus. Lupus 2004;13:869-76
   PubMed Web of Science ®Google Scholar
• Merrill JT. Diagnosis of the antiphospholipid syndrome: how far to go?. Curr Rheumatol Rep 2004;6:469-72
   PubMedGoogle Scholar
• Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 1999;38:917-32
   PubMed Web of Science ®Google Scholar
• Hallegua DS, Wallace DJ. Gastrointestinal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol 2000;12:379-85
   PubMed Web of Science ®Google Scholar
• Lee CK, Ahn MS, Lee EY, et al. Acute abdominal pain in systemic lupus erythematosus: focus on lupus enteritis (gastrointestinal vasculitis). Ann Rheum Dis 2002;61:547-50
   PubMed Web of Science ®Google Scholar
• Kozora E, Arciniegas DB, Zhang L, et al. Neuropsychological patterns in systemic lupus erythematosus patients with depression. Arthritis Res Ther 2007;9:R48
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Galindo-Rodriguez G, Robledo I, et al. Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus. Lupus 2003;12:52-7
   PubMed Web of Science ®Google Scholar
• Rivero SJ, Diaz-Jouanen E, Alarcon-Segovia D. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum 1978;21:295-305
   PubMed Web of Science ®Google Scholar
• Kao AH, Manzi S, Ramsey-Goldman R. Review of ACR hematologic criteria in systemic lupus erythematosus. Lupus 2004;13:865-8
   PubMed Web of Science ®Google Scholar
• Ng WL, Chu CM, Wu AK, et al. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM 2006;99:37-47
   PubMed Web of Science ®Google Scholar
• Merrill JT, Asherson RA. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol 2006;2:81-9
   PubMedGoogle Scholar
• Kasparian A, Floros A, Gialafos E, et al. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus. Lupus 2007;16:505-8
   PubMed Web of Science ®Google Scholar
• Peura DA, Goldkind L. Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. Arthritis Res Ther 2005;7(Suppl 4):S7-13
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006;296:1619-32
   PubMed Web of Science ®Google Scholar
• O'Connor N, Dargan PI, Jones AL. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM 2003;96:787-91
   PubMed Web of Science ®Google Scholar
• Ostensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus 2001;10:135-9
   PubMed Web of Science ®Google Scholar
• Parker BJ, Bruce IN. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus. Lupus 2007;16:387-93
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Barr SG, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801-8
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9
   PubMed Web of Science ®Google Scholar
• Yeap SS, Hosking DJ. Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford) 2002;41:1088-94
   PubMed Web of Science ®Google Scholar
• Mok CC, Mak A, Ma KM. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 2005;14:106-12
   PubMedGoogle Scholar
• Jaovisidha S, Denprechawong R, Suwannalai P, et al. Asymptomatic avascular osteonecrosis of the hip in new patients diagnosed as systemic lupus erythematosus in Ramathibodi Hospital. J Med Assoc Thai 2007;90:1382-90
   PubMedGoogle Scholar
• Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60
   PubMed Web of Science ®Google Scholar
• Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000;9:170-5
   PubMed Web of Science ®Google Scholar
• Peponis V, Kyttaris VC, Tyradellis C, et al. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus 2006;15:3-12
   PubMed Web of Science ®Google Scholar
• Easterbrook M. Ocular effects and safety of antimalarial agents. Am J Med 1988;85:23-9
   PubMed Web of Science ®Google Scholar
• Lloyd LA, Hiltz JW. Ocular complications of chloroquine therapy. Can Med Assoc J 1965;92:508-13
   PubMed Web of Science ®Google Scholar
• Nord JE, Shah PK, Rinaldi RZ, et al. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 2004;33:336-51
   PubMed Web of Science ®Google Scholar
• Park MC, Park YB, Jung SY, et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004;13:569-74
   PubMed Web of Science ®Google Scholar
• Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-7
   PubMed Web of Science ®Google Scholar
• Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-19
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin III HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996;125:549-57
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28
   PubMed Web of Science ®Google Scholar
• McCune WJ. Mycophenolate mofetil for lupus nephritis. N Engl J Med 2005;353:2282-4
   PubMed Web of Science ®Google Scholar
• Riskalla MM, Somers EC, Fatica RA, et al. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1508-12
   PubMed Web of Science ®Google Scholar
• Pisoni CN, Sanchez FJ, Karim Y, et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005;32:1047-52
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006;8:R182
   PubMed Web of Science ®Google Scholar
• Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001;10:162-4
   PubMed Web of Science ®Google Scholar
• Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999;26:1275-9
   PubMed Web of Science ®Google Scholar
• Rahman P, Humphrey-Murto S, Gladman DD, et al. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol 1998;25:243-6
   PubMed Web of Science ®Google Scholar
• Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006;1:925-32
   PubMed Web of Science ®Google Scholar
• Wallace DJ. What's new in the management of lupus since 2000?. J Clin Rheumatol 2006;12:307-13
   PubMed Web of Science ®Google Scholar
• Neumann D, Tschernig T, Boraschi D. Development of biologicals for the therapy of lupus erythematosus. Expert Rev Vaccines 2007;6:1001-11
   PubMed Web of Science ®Google Scholar
• Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005;19:859-78
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER. ACR/ARHP annual scientific meeting. San Francisco, USA, October 24–29, 2008 [Abstract No. L12] b
   Google Scholar
• Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-90
   PubMed Web of Science ®Google Scholar
• Carnahan J, Stein R, Qu Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007;44:1331-41
   PubMed Web of Science ®Google Scholar
• Dörner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
   PubMed Web of Science ®Google Scholar
• Steinfeld SD, Youinou P. Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther 2006;6:943-9
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51
   PubMed Web of Science ®Google Scholar
• Aringer M, Graninger WB, Steiner G, et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9
   PubMed Web of Science ®Google Scholar
• Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006;65(Suppl 3):iii34-6
   PubMedGoogle Scholar
• Kahn K. Belimumab may be effective treatment for SLE. Medscape Medical News 2007. Available at: http://www.medscape.com/viewarticle/565710
   Google Scholar
• Wallace DJ, Lisse J, Stohl W, et al. Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks. Arthritis Rheum 2006;54(Suppl 9):S790
   Google Scholar
• Orencia® [abatacept] prescribing information. http://www bms com/cgi-bin/anybin pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=111&key=PPI,2007. Available at: http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20TB_PRODUCT_PPI %20where%20PPI_SEQ=111&key=PPI
   Google Scholar
• Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study. ACR/ARHP annual scientific meeting. San Francisco, USA, October 24–29, 2008 [Abstract No. L15] a
   Google Scholar
• Merrill JT, Levin R, Chindalore V, et al. Safety of MEDI-545, an anti-interferonα monoclonal antibody, in MI-CP126, a phase I study in systemic lupus erythematosus (SLE). Arthritis Rheum 2007;56(Suppl 9):S210
   Google Scholar
• Wallace DJ, Petri M, Olsen N, et al. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum 2007;56(Suppl9):S526
   Google Scholar
• Mosca M, Baldini C, Bombardieri S. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus. Expert Opin Pharmacother 2007;8:873-9
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Tumlin JA. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 2004;13:323-7
   PubMed Web of Science ®Google Scholar
• Crosbie D, Black C, McIntyre L, et al. Dehydroepiandrosterone for systemic lupus erythematosus. Cochrane Database Syst Rev 2007;(4):CD005114
   Google Scholar